Nvidia disclosed in recent regulatory filings that it had fully exited its roughly two‑year, 7.71 million‑share investment in Recursion Pharmaceuticals, while Cathie Wood’s ARK Invest simultaneously ...

Nvidia's positions in these companies were relatively small at the end of the third quarter of 2025, but the chipmaker has spent recent years building a portfolio of AI‑related investments across ...

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. If you are trying to figure out whether Recursion Pharmaceuticals is ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

The co-founders of startup Ricursive Intelligence seemed destined to be co-founders. Anna Goldie, CEO, and Azalia Mirhoseini, CTO, are so well-known in the AI community that they were among those AI ...

The pharmaceutical market, worth $1.7 trillion, offers stable long-term investment opportunities. Top pharma stocks like AbbVie and Pfizer are poised for growth despite patent challenges. Invest in ...